| Item Type | Name |
|
Concept
|
Oncogene Protein v-akt
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Proto-Oncogene Proteins B-raf
|
|
Concept
|
Oncogene Proteins
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Proto-Oncogene Proteins
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-6
|
|
Academic Article
|
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
|
|
Academic Article
|
KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients.
|
|
Academic Article
|
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
|
|
Academic Article
|
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
|
|
Academic Article
|
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
|
|
Academic Article
|
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
|
|
Academic Article
|
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
|
|
Academic Article
|
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
|
|
Academic Article
|
STAT3 inhibitors: finding a home in lymphoma and leukemia.
|
|
Academic Article
|
Response of histiocytoses to imatinib mesylate: fire to ashes.
|
|
Academic Article
|
BRAF mutations in advanced cancers: clinical characteristics and outcomes.
|
|
Academic Article
|
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
|
Academic Article
|
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
|
|
Academic Article
|
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
|
|
Academic Article
|
PIK3CA mutations in advanced cancers: characteristics and outcomes.
|
|
Academic Article
|
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
|
|
Academic Article
|
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
|
|
Academic Article
|
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
|
|
Academic Article
|
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
|
|
Academic Article
|
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
|
|
Academic Article
|
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
|
|
Academic Article
|
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.
|
|
Academic Article
|
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
|
|
Academic Article
|
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
|
|
Academic Article
|
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
|
|
Academic Article
|
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
|
|
Academic Article
|
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
|
|
Academic Article
|
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
|
|
Academic Article
|
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
|
|
Academic Article
|
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
|
|
Academic Article
|
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
|
|
Academic Article
|
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
|
|
Academic Article
|
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.
|
|
Academic Article
|
Cell-free DNA as a novel marker in cancer therapy.
|
|
Academic Article
|
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
|
|
Academic Article
|
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
|
|
Academic Article
|
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
|
|
Academic Article
|
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
|
|
Academic Article
|
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
|
|
Academic Article
|
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
|
|
Academic Article
|
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
|
|
Academic Article
|
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
|
|
Academic Article
|
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
|
|
Academic Article
|
International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.
|
|
Academic Article
|
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.
|
|
Academic Article
|
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
|
|
Academic Article
|
Advances on the BRAF Front in Colorectal Cancer.
|
|
Academic Article
|
Targeting the PI3K pathway in cancer: are we making headway?
|
|
Academic Article
|
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
|
|
Academic Article
|
BRAF alterations in primary brain tumors.
|
|
Academic Article
|
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
|
|
Academic Article
|
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
|
|
Academic Article
|
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
|
|
Academic Article
|
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
|
|
Academic Article
|
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
|
|
Academic Article
|
Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.
|
|
Academic Article
|
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
|
|
Academic Article
|
Hormonal modulation of ESR1 mutant metastasis.
|
|
Academic Article
|
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
|
|
Academic Article
|
Correction to: Hormonal modulation of ESR1 mutant metastasis.
|
|
Academic Article
|
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.
|
|
Academic Article
|
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer.
|
|
Academic Article
|
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
|
|
Academic Article
|
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.
|
|
Academic Article
|
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
|
|
Academic Article
|
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
|
|
Academic Article
|
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
|